Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3D1002 + oxycodone
- Development stage
- Unknown
- Lead developer
- 3D Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
3D1002 + oxycodone is an investigational drug combination being studied for the management of moderate to severe cancer pain. 3D1002 is a selective antagonist of the prostaglandin E2 receptor subtype 4 (EP4), developed to target pain pathways associated with cancer. Oxycodone is a potent semisynthetic opioid agonist that acts primarily on mu-, kappa-, and delta-type opioid receptors in the central nervous system, providing analgesia for severe pain. The combination aims to enhance pain relief by targeting both inflammatory and opioid-mediated mechanisms. Clinical trials are ongoing to evaluate safety and efficacy, with Phase II studies comparing this combination against oxycodone alone[1][3][6][8].
- Brand names
- Eth-OxydoseOxyCONTIN CROxydoseOxyfastRoxicodone IntensolXtampza ER
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on 3D1002 + oxycodone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3D1002 + oxycodone.